Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q3

4671.TEDINET S100Q645
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥35.9bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥50.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥36.4bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥2.5bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥3.8bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥2.7bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.1bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥2.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥4.0bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥38.3bnat 2022-12-31Cons.Assets
Total assets¥40.3bnat 2022-03-31Cons.Assets
Total assets¥38.7bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥13.6bnat 2022-12-31Cons.Liabilities
Total liabilities¥16.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥24.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥23.5bnat 2022-03-31Cons.Net assets
Net assets / equity¥22.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥10.0bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥10.6bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥146.882022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥39.432022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3392021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥242.322021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.082021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥146.232022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥336.992021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥241.232021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio64.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.6%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥362m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥23.9bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥23.9bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥590m
—segment totalrevenue2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.9bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥12m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥12m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥279m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥24.2bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥24.2bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥11m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥12.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥12.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥770m
—segment totalrevenue2021-04-01 → 2021-12-31¥36.5bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥36.4bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥12m
—segment totalsegment profit2021-04-01 → 2021-12-31¥4.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 355
ItemContextValueUnit
Investment securitiesPrior1YearInstant3801000000JPY
Investment securitiesCurrentQuarterInstant3950000000JPY
Other ioaPrior1YearInstant2641000000JPY
Other ioaCurrentQuarterInstant2692000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-8000000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-8000000JPY
Investments and other assetsPrior1YearInstant6434000000JPY
Investments and other assetsCurrentQuarterInstant6634000000JPY
Noncurrent assetsPrior1YearInstant17588000000JPY
Noncurrent assetsCurrentQuarterInstant17521000000JPY
AssetsPrior1YearInstant40256000000JPY
AssetsCurrentQuarterInstant38317000000JPY
Notes and accounts payable tradePrior1YearInstant5384000000JPY
Notes and accounts payable tradeCurrentQuarterInstant5324000000JPY
Short term loans payablePrior1YearInstant300000000JPY
Short term loans payableCurrentQuarterInstant200000000JPY
Current portion of long term loans payablePrior1YearInstant715000000JPY
Current portion of long term loans payableCurrentQuarterInstant2340000000JPY
Income taxes payablePrior1YearInstant1725000000JPY
Income taxes payableCurrentQuarterInstant58000000JPY
Provision clPrior1YearInstant610000000JPY
Provision clCurrentQuarterInstant196000000JPY
Other clPrior1YearInstant2652000000JPY
Other clCurrentQuarterInstant2587000000JPY
Current liabilitiesPrior1YearInstant11389000000JPY
Current liabilitiesCurrentQuarterInstant10706000000JPY
Long term loans payablePrior1YearInstant2340000000JPY
Long term loans payableCurrentQuarterInstant－JPY
Net defined benefit liabilityPrior1YearInstant1919000000JPY
Net defined benefit liabilityCurrentQuarterInstant1869000000JPY
Asset retirement obligations nclPrior1YearInstant133000000JPY
Asset retirement obligations nclCurrentQuarterInstant135000000JPY
Other nclPrior1YearInstant995000000JPY
Other nclCurrentQuarterInstant914000000JPY
Noncurrent liabilitiesPrior1YearInstant5389000000JPY
Noncurrent liabilitiesCurrentQuarterInstant2919000000JPY
LiabilitiesPrior1YearInstant16778000000JPY
LiabilitiesCurrentQuarterInstant13626000000JPY
Capital stockPrior1YearInstant3371000000JPY
Capital stockCurrentQuarterInstant3371000000JPY
Capital surplusPrior1YearInstant3387000000JPY
Capital surplusCurrentQuarterInstant3387000000JPY
Retained earningsPrior1YearInstant17479000000JPY
Retained earningsCurrentQuarterInstant18304000000JPY
Treasury stockPrior1YearInstant-1343000000JPY
Treasury stockCurrentQuarterInstant-1238000000JPY
Shareholders equityPrior1YearInstant22895000000JPY
Shareholders equityCurrentQuarterInstant23824000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant500000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant783000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass